Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 16/20 | 0.46 |
| ▸ | HTR2B | P41595 | 16/20 | 0.46 |
| ▸ | HTR2A | P28223 | 15/20 | 0.46 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.38 |
| ▸ | HTR3B | O95264 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.38 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.38 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29966514 | 1.00 | PARP1 (0.46) | PARP1HTR2CHTR2BHTR2AHTR3E | |
| SCHEMBL26625271 | 1.00 | PARP1 (0.46) | PARP1HTR2CHTR2BHTR2AHTR3E | |
| SCHEMBL30747194 | 0.91 | PARP1 (0.46) | PARP1HTR2CHTR2BHTR2AHTR3E | |
| SCHEMBL30069799 | 0.91 | PARP1 (0.46) | PARP1HTR2CHTR2BHTR2AHTR3E | |
| SCHEMBL32664871 | 0.87 | PARP1 (0.41) | PARP1HTR2CHTR2BHTR2AHTR3E | |
| SCHEMBL29975791 | 0.87 | ESR1 (0.41) | PARP1HTR2CHTR2BHTR2AHTR3E | |
| SCHEMBL30002807 | 0.86 | PARP1 (0.44) | PARP1HTR2CHTR2BHTR2AHTR3E | |
| SCHEMBL30702593 | 0.86 | PARP1 (0.44) | PARP1HTR2CHTR2BHTR2AHTR3E | |
| SCHEMBL30351677 | 0.85 | PARP1 (0.43) | PARP1HTR2CHTR2BHTR2AHTR3E | |
| SCHEMBL30801290 | 0.85 | PARP1 (0.40) | PARP1HTR2CHTR2BHTR2AHTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177539-A1 | ER DEGRADERS AND USES THEREOF | ASTRAZENECA AB (SE) | 2025-06-05 | — | — | US | disclosed |
| EP-4317146-A1 | TETRAHYDRONAPHTHALENE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022206737-A1 | TETRAHYDRONAPHTHALENE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | 江苏恒瑞医药股份有限公司 | 2022-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250177539-A1 | ER DEGRADERS AND USES THEREOF | ESR1, ESR2, ESRRA | PARP1 4046/4885HTR2C 1836/4885HTR2B 2060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.